amiselimod vs etrasimod

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Ulcerative Colitis

Shared mechanism: S1P receptor · full Ulcerative Colitis pipeline

amiselimod

Developed by Bausch Health under a licence from Tanabe Pharma Corporation

Phase 2 in Ulcerative ColitisSmall molecule (oral S1P receptor modulator)
Reliable signal

NCT04857112 · Phase 2 · completed

This trial randomly assigned 322 people with ulcerative colitis to one of two amiselimod doses or placebo, with participants and investigators unaware of assignment. The primary measure was change in the modified Mayo Score, which combines the appearance of the bowel lining at endoscopy with clinical disease activity. Scores fell by 2.3 points on amiselimod against 1.6 points on placebo (p=0.002).

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Reported efficacy

Change from Baseline in the modified Mayo Score at Day 85 (Baseline to Day 85): Change from baseline in modified Mayo Score at Day 85: amiselimod -2.3 vs placebo -1.6 (p=0.002) (met)

Result source: NCT04857112

etrasimod · Velsipity

Marketed by Pfizer and partners

Approved in Ulcerative ColitisSmall molecule (S1P1,4,5 modulator)
Reliable signal

NCT03945188 · Phase 3 · completed

Randomized 2:1, double-blind, placebo-controlled, adequately powered (n=433) phase 3 trial with a hard clinical/endoscopic composite primary endpoint (clinical remission via modified Mayo score incorporating centrally-read endoscopy), and both co-primary endpoint comparisons reached statistical significance in the favorable direction (p<0.001), satisfying the 'strong' definition.

Next expected readout: June 2027 · NCT07782242 (registry estimate)

Reported efficacy

Percentage of Participants Achieving Clinical Remission at Week 12; Percentage of Participants Achieving Clinical Remission at Week 52: Percentage of Participants Achieving Clinical Remission at Week 12 (At Week 12): Etrasimod 2 mg 27.0% vs Placebo 7.4%; p=<0.001 (Etrasimod 2 mg vs Placebo) (met)

Result source: NCT03945188

Results for Ulcerative Colitis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointamiselimodetrasimod
Clinical remission (induction)—Not reported27% vs 7.4%+19.6 vs placebo2 mg · wk 12 · n 274NCT03945188
6 other results
  • 24.8% vs 15.2% 2 mg · wk 12 · n 222 · Phase 3 · primary NCT03996369
  • 26.3% vs 0% 2 mg · wk 12 · n 19 · Phase 2 · primary NCT05061446
  • 6.7% vs 0% 1 mg · wk 12 · n 15 · Phase 2 · primary NCT05061446
  • 33% vs 8.1% 2 mg · wk 12 · n 50 · Phase 2 · secondary NCT02447302
  • 16% vs 8.1% 1 mg · wk 12 · n 52 · Phase 2 · secondary NCT02447302
  • 28.3% vs 11.7% wk 12 · n 127 · Phase 2 · secondary NCT04607837
Clinical remission (maintenance)—Not reported32.1% vs 6.7%+25.4 vs placebo2 mg · wk 52 · n 274NCT03945188
3 other results
  • 25% vs 7.1% 2 mg · wk 40 · n 28 · Phase 3 · primary NCT04706793
  • 49.1% vs 17.4% 2 mg · wk 52 · n 171 · Phase 3 · secondary NCT03945188
  • 26% vs 18.3% wk 52 · n 127 · Phase 2 · primary NCT04607837
Clinical response (induction)—Not reported62.4% vs 34.1%+28.3 vs placebo2 mg · wk 12 · n 274NCT03945188
6 other results
  • 62.2% vs 41.1% 2 mg · wk 12 · n 222 · Phase 3 · secondary NCT03996369
  • 50.6% vs 32.5% 2 mg · wk 12 · n 50 · Phase 2 · secondary NCT02447302
  • 43.7% vs 32.5% 1 mg · wk 12 · n 52 · Phase 2 · secondary NCT02447302
  • 55.9% vs 36.7% wk 12 · n 127 · Phase 2 · secondary NCT04607837
  • 52.6% vs 7.1% 2 mg · wk 12 · n 19 · Phase 2 · secondary NCT05061446
  • 33.3% vs 7.1% 1 mg · wk 12 · n 15 · Phase 2 · secondary NCT05061446
Endoscopic improvement (induction)—Not reported35% vs 14.1%+20.9 vs placebo2 mg · wk 12 · n 274NCT03945188
6 other results
  • 30.6% vs 18.8% 2 mg · wk 12 · n 222 · Phase 3 · secondary NCT03996369
  • 41.8% vs 17.8% 2 mg · wk 12 · n 50 · Phase 2 · secondary NCT02447302
  • 22.5% vs 17.8% 1 mg · wk 12 · n 52 · Phase 2 · secondary NCT02447302
  • 44.1% vs 20% wk 12 · n 127 · Phase 2 · secondary NCT04607837
  • 26.3% vs 0% 2 mg · wk 12 · n 19 · Phase 2 · secondary NCT05061446
  • 6.7% vs 0% 1 mg · wk 12 · n 15 · Phase 2 · secondary NCT05061446
Corticosteroid-free remission (maintenance)—Not reported32.1% vs 6.7%+25.4 vs placebo2 mg · wk 52 · n 274NCT03945188
6 other results
  • 31% vs 7.5% 2 mg · wk 52 · n 87 · Phase 3 · secondary NCT03945188
  • 25% vs 7.1% 2 mg · wk 40 · n 28 · Phase 3 · secondary NCT04706793
  • 25.2% vs 16.7% wk 52 · n 127 · Phase 2 · secondary NCT04607837
  • 25.2% vs 16.7% wk 52 · n 127 · Phase 2 · secondary NCT04607837
  • 16.2% vs 16.7% wk 52 · n 37 · Phase 2 · secondary NCT04607837
  • 30% vs 30% wk 52 · n 20 · Phase 2 · secondary NCT04607837

Clinical remission (induction)

amiselimod
—Not reported
etrasimod
27% vs 7.4%+19.6 vs placebo2 mg · wk 12 · n 274NCT03945188
6 other results
  • 24.8% vs 15.2% 2 mg · wk 12 · n 222 · Phase 3 · primary NCT03996369
  • 26.3% vs 0% 2 mg · wk 12 · n 19 · Phase 2 · primary NCT05061446
  • 6.7% vs 0% 1 mg · wk 12 · n 15 · Phase 2 · primary NCT05061446
  • 33% vs 8.1% 2 mg · wk 12 · n 50 · Phase 2 · secondary NCT02447302
  • 16% vs 8.1% 1 mg · wk 12 · n 52 · Phase 2 · secondary NCT02447302
  • 28.3% vs 11.7% wk 12 · n 127 · Phase 2 · secondary NCT04607837

Clinical remission (maintenance)

amiselimod
—Not reported
etrasimod
32.1% vs 6.7%+25.4 vs placebo2 mg · wk 52 · n 274NCT03945188
3 other results
  • 25% vs 7.1% 2 mg · wk 40 · n 28 · Phase 3 · primary NCT04706793
  • 49.1% vs 17.4% 2 mg · wk 52 · n 171 · Phase 3 · secondary NCT03945188
  • 26% vs 18.3% wk 52 · n 127 · Phase 2 · primary NCT04607837

Clinical response (induction)

amiselimod
—Not reported
etrasimod
62.4% vs 34.1%+28.3 vs placebo2 mg · wk 12 · n 274NCT03945188
6 other results
  • 62.2% vs 41.1% 2 mg · wk 12 · n 222 · Phase 3 · secondary NCT03996369
  • 50.6% vs 32.5% 2 mg · wk 12 · n 50 · Phase 2 · secondary NCT02447302
  • 43.7% vs 32.5% 1 mg · wk 12 · n 52 · Phase 2 · secondary NCT02447302
  • 55.9% vs 36.7% wk 12 · n 127 · Phase 2 · secondary NCT04607837
  • 52.6% vs 7.1% 2 mg · wk 12 · n 19 · Phase 2 · secondary NCT05061446
  • 33.3% vs 7.1% 1 mg · wk 12 · n 15 · Phase 2 · secondary NCT05061446

Endoscopic improvement (induction)

amiselimod
—Not reported
etrasimod
35% vs 14.1%+20.9 vs placebo2 mg · wk 12 · n 274NCT03945188
6 other results
  • 30.6% vs 18.8% 2 mg · wk 12 · n 222 · Phase 3 · secondary NCT03996369
  • 41.8% vs 17.8% 2 mg · wk 12 · n 50 · Phase 2 · secondary NCT02447302
  • 22.5% vs 17.8% 1 mg · wk 12 · n 52 · Phase 2 · secondary NCT02447302
  • 44.1% vs 20% wk 12 · n 127 · Phase 2 · secondary NCT04607837
  • 26.3% vs 0% 2 mg · wk 12 · n 19 · Phase 2 · secondary NCT05061446
  • 6.7% vs 0% 1 mg · wk 12 · n 15 · Phase 2 · secondary NCT05061446

Corticosteroid-free remission (maintenance)

amiselimod
—Not reported
etrasimod
32.1% vs 6.7%+25.4 vs placebo2 mg · wk 52 · n 274NCT03945188
6 other results
  • 31% vs 7.5% 2 mg · wk 52 · n 87 · Phase 3 · secondary NCT03945188
  • 25% vs 7.1% 2 mg · wk 40 · n 28 · Phase 3 · secondary NCT04706793
  • 25.2% vs 16.7% wk 52 · n 127 · Phase 2 · secondary NCT04607837
  • 25.2% vs 16.7% wk 52 · n 127 · Phase 2 · secondary NCT04607837
  • 16.2% vs 16.7% wk 52 · n 37 · Phase 2 · secondary NCT04607837
  • 30% vs 30% wk 52 · n 20 · Phase 2 · secondary NCT04607837
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety

Coverage. amiselimod: 1 of 5 rows · etrasimod: 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricamiselimodetrasimod
Mayo 9
absolute change · score
Induction
-2.3 vs -1.6 placebo score @ 12.142857wka,b,c
NCT04857112 · Phase 2 · sponsor-reported, not registry data
-2.49 vs -1.5 placebo score @ 12wk2 mgd,a,b,c
NCT02447302 · Phase 2 · registry result, not featured evidence
show 1 more dose
-1.94 vs -1.5 placebo score @ 12wk1 mg
NCT02447302 · Phase 2 · registry result, not featured evidence
Dropout rate—
44.3%2 mge
NCT03945188 · Phase 3 · monotherapy
show 8 more results
10.5%2 mg
NCT03996369 · Phase 3 · monotherapy
35.7%2 mg
NCT04706793 · Phase 3 · monotherapy
37.4%
NCT04607837 · Phase 2 · registry result, not featured evidence
0%2 mg
NCT05061446 · Phase 2 · registry result, not featured evidence
5.9%1 mg
NCT05061446 · Phase 2 · registry result, not featured evidence
17.9%2 mg
NCT02536404 · Phase 2 · registry result, not featured evidence
8%2 mg
NCT02447302 · Phase 2 · registry result, not featured evidence
9.6%1 mg
NCT02447302 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs—
3.5%2 mge
NCT03945188 · Phase 3 · monotherapy
show 8 more results
3.8%2 mg
NCT03996369 · Phase 3 · monotherapy
—2 mg
NCT04706793 · Phase 3 · monotherapy
5.2%
NCT04607837 · Phase 2 · registry result, not featured evidence
0%2 mg
NCT05061446 · Phase 2 · registry result, not featured evidence
0%1 mg
NCT05061446 · Phase 2 · registry result, not featured evidence
4.5%2 mg
NCT02536404 · Phase 2 · registry result, not featured evidence
6%2 mg
NCT02447302 · Phase 2 · registry result, not featured evidence
7.7%1 mg
NCT02447302 · Phase 2 · registry result, not featured evidence
Serious AEs—
6.9%2 mge
NCT03945188 · Phase 3 · monotherapy
show 8 more results
2.5%2 mg
NCT03996369 · Phase 3 · monotherapy
3.6%2 mg
NCT04706793 · Phase 3 · monotherapy
6.5%
NCT04607837 · Phase 2 · registry result, not featured evidence
0%2 mg
NCT05061446 · Phase 2 · registry result, not featured evidence
0%1 mg
NCT05061446 · Phase 2 · registry result, not featured evidence
6.3%2 mg
NCT02536404 · Phase 2 · registry result, not featured evidence
0%2 mg
NCT02447302 · Phase 2 · registry result, not featured evidence
5.8%1 mg
NCT02447302 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs—
2 mge
anaemia 8.3% (placebo 9.7%)
headache 8.3% (placebo 4.9%)
covid-19 6.6% (placebo 5.6%)
NCT03945188 · Phase 3 · monotherapy
show 8 more results
2 mg
anaemia 5.9% (placebo 6.9%)
headache 4.6% (placebo 1.7%)
nausea 4.2% (placebo 1.7%)
NCT03996369 · Phase 3 · monotherapy
2 mg
headache 14.3% (placebo 14.3%)
malaise 10.7% (placebo 0%)
pyrexia 10.7% (placebo 14.3%)
NCT04706793 · Phase 3 · monotherapy
colitis ulcerative 12.3% (placebo 10.1%)
covid-19 9.7% (placebo 8.9%)
alanine aminotransferase increased 8.4% (placebo 1.3%)
NCT04607837 · Phase 2 · registry result, not featured evidence
2 mg
alanine aminotransferase increased 5.3% (placebo 0%)
back pain 5.3% (placebo 0%)
blood creatine phosphokinase increased 5.3% (placebo 0%)
NCT05061446 · Phase 2 · registry result, not featured evidence
1 mg
stomatitis 11.8% (placebo 0%)
anaemia 5.9% (placebo 0%)
cataract 5.9% (placebo 0%)
NCT05061446 · Phase 2 · registry result, not featured evidence
2 mg
colitis ulcerative 14.3% (placebo 16.7%)
anaemia 8.9% (placebo 0%)
gamma-glutamyltransferase increased 8.9% (placebo 0%)
NCT02536404 · Phase 2 · registry result, not featured evidence
2 mg
anaemia 6% (placebo 3.7%)
headache 6% (placebo 1.9%)
colitis ulcerative 4% (placebo 1.9%)
NCT02447302 · Phase 2 · registry result, not featured evidence
1 mg
upper respiratory tract infection 7.7% (placebo 3.7%)
colitis ulcerative 5.8% (placebo 1.9%)
anaemia 3.8% (placebo 3.7%)
NCT02447302 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for both studies.
  2. bTreatment context has not been resolved for both arms.
  3. cAssessment timepoints differ: 12 weeks versus 12.142857 weeks.
  4. dThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  5. ePopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

etrasimod

Clinical Remission 27% (n=274) vs 7.4% (n=135) placebo @ 12wk2 mg
responder rate · % of participants
NCT03945188 · Phase 3 · monotherapy
show 10 more results
32.1% (n=274) vs 6.7% (n=135) placebo @ 52wk2 mg
NCT03945188 · Phase 3 · monotherapy
49.1% (n=171) vs 17.4% (n=46) placebo @ 52wk2 mg
NCT03945188 · Phase 3 · monotherapy
24.8% (n=222) vs 15.2% (n=112) placebo @ 12wk2 mg
NCT03996369 · Phase 3 · monotherapy
25% (n=28) vs 7.1% (n=14) placebo @ 40wk2 mg
NCT04706793 · Phase 3 · monotherapy
26.3% (n=19) vs 0% (n=14) placebo @ 12wk2 mg
NCT05061446 · Phase 2 · registry result, not featured evidence
33% (n=50) vs 8.1% (n=54) placebo @ 12wk2 mg
NCT02447302 · Phase 2 · registry result, not featured evidence
6.7% (n=15) vs 0% (n=14) placebo @ 12wk1 mg
NCT05061446 · Phase 2 · registry result, not featured evidence
16% (n=52) vs 8.1% (n=54) placebo @ 12wk1 mg
NCT02447302 · Phase 2 · registry result, not featured evidence
26% (n=127) vs 18.3% (n=60) placebo @ 52wk
NCT04607837 · Phase 2 · registry result, not featured evidence
28.3% (n=127) vs 11.7% (n=60) placebo @ 12wk
NCT04607837 · Phase 2 · registry result, not featured evidence
Endoscopic Improvement 35% (n=274) vs 14.1% (n=135) placebo @ 12wk2 mg
responder rate · % of participants
NCT03945188 · Phase 3 · monotherapy
show 9 more results
37.2% (n=274) vs 10.4% (n=135) placebo @ 52wk2 mg
NCT03945188 · Phase 3 · monotherapy
30.6% (n=222) vs 18.8% (n=112) placebo @ 12wk2 mg
NCT03996369 · Phase 3 · monotherapy
35.7% (n=28) vs 7.1% (n=14) placebo @ 40wk2 mg
NCT04706793 · Phase 3 · monotherapy
26.3% (n=19) vs 0% (n=14) placebo @ 12wk2 mg
NCT05061446 · Phase 2 · registry result, not featured evidence
41.8% (n=50) vs 17.8% (n=54) placebo @ 12wk2 mg
NCT02447302 · Phase 2 · registry result, not featured evidence
6.7% (n=15) vs 0% (n=14) placebo @ 12wk1 mg
NCT05061446 · Phase 2 · registry result, not featured evidence
22.5% (n=52) vs 17.8% (n=54) placebo @ 12wk1 mg
NCT02447302 · Phase 2 · registry result, not featured evidence
32.3% (n=127) vs 23.3% (n=60) placebo @ 52wk
NCT04607837 · Phase 2 · registry result, not featured evidence
44.1% (n=127) vs 20% (n=60) placebo @ 12wk
NCT04607837 · Phase 2 · registry result, not featured evidence
Symptomatic Remission 46% (n=274) vs 21.5% (n=135) placebo @ 12wk2 mg
responder rate · % of participants
NCT03945188 · Phase 3 · monotherapy
show 19 more results
43.4% (n=274) vs 18.5% (n=135) placebo @ 52wk2 mg
NCT03945188 · Phase 3 · monotherapy
15.3% (n=274) vs 8.9% (n=135) placebo @ 2wk2 mg
NCT03945188 · Phase 3 · monotherapy
28.1% (n=274) vs 13.3% (n=135) placebo @ 4wk2 mg
NCT03945188 · Phase 3 · monotherapy
37.6% (n=274) vs 20.7% (n=135) placebo @ 8wk2 mg
NCT03945188 · Phase 3 · monotherapy
43.1% (n=274) vs 21.5% (n=135) placebo @ 16wk2 mg
NCT03945188 · Phase 3 · monotherapy
43.8% (n=274) vs 20% (n=135) placebo @ 20wk2 mg
NCT03945188 · Phase 3 · monotherapy
44.9% (n=274) vs 23.7% (n=135) placebo @ 24wk2 mg
NCT03945188 · Phase 3 · monotherapy
44.5% (n=274) vs 18.5% (n=135) placebo @ 32wk2 mg
NCT03945188 · Phase 3 · monotherapy
42% (n=274) vs 18.5% (n=135) placebo @ 40wk2 mg
NCT03945188 · Phase 3 · monotherapy
42% (n=274) vs 15.6% (n=135) placebo @ 48wk2 mg
NCT03945188 · Phase 3 · monotherapy
46.8% (n=222) vs 29.5% (n=112) placebo @ 12wk2 mg
NCT03996369 · Phase 3 · monotherapy
16.2% (n=222) vs 10.7% (n=112) placebo @ 2wk2 mg
NCT03996369 · Phase 3 · monotherapy
27.5% (n=222) vs 16.1% (n=112) placebo @ 4wk2 mg
NCT03996369 · Phase 3 · monotherapy
38.7% (n=222) vs 24.1% (n=112) placebo @ 8wk2 mg
NCT03996369 · Phase 3 · monotherapy
39.3% (n=28) vs 7.1% (n=14) placebo @ 40wk2 mg
NCT04706793 · Phase 3 · monotherapy
31.6% (n=19) vs 0% (n=14) placebo @ 12wk2 mg
NCT05061446 · Phase 2 · registry result, not featured evidence
20% (n=15) vs 0% (n=14) placebo @ 12wk1 mg
NCT05061446 · Phase 2 · registry result, not featured evidence
37% (n=127) vs 30% (n=60) placebo @ 52wk
NCT04607837 · Phase 2 · registry result, not featured evidence
36.2% (n=127) vs 25% (n=60) placebo @ 12wk
NCT04607837 · Phase 2 · registry result, not featured evidence
Mucosal Healing 21.2% (n=274) vs 4.4% (n=135) placebo @ 12wk2 mg
responder rate · % of participants
NCT03945188 · Phase 3 · monotherapy
show 5 more results
26.6% (n=274) vs 8.1% (n=135) placebo @ 52wk2 mg
NCT03945188 · Phase 3 · monotherapy
16.2% (n=222) vs 8.9% (n=112) placebo @ 12wk2 mg
NCT03996369 · Phase 3 · monotherapy
28.6% (n=28) vs 7.1% (n=14) placebo @ 40wk2 mg
NCT04706793 · Phase 3 · monotherapy
5.3% (n=19) vs 0% (n=14) placebo @ 12wk2 mg
NCT05061446 · Phase 2 · registry result, not featured evidence
6.7% (n=15) vs 0% (n=14) placebo @ 12wk1 mg
NCT05061446 · Phase 2 · registry result, not featured evidence
Corticosteroid-free Clinical Remission 32.1% (n=274) vs 6.7% (n=135) placebo @ 52wk2 mg
responder rate · % of participants
NCT03945188 · Phase 3 · monotherapy
show 6 more results
31% (n=87) vs 7.5% (n=40) placebo @ 52wk2 mg
NCT03945188 · Phase 3 · monotherapy
25% (n=28) vs 7.1% (n=14) placebo @ 40wk2 mg
NCT04706793 · Phase 3 · monotherapy
16.2% (n=37) vs 16.7% (n=18) placebo @ 52wk
NCT04607837 · Phase 2 · registry result, not featured evidence
25.2% (n=127) vs 16.7% (n=60) placebo @ 52wk
NCT04607837 · Phase 2 · registry result, not featured evidence
30% (n=20) vs 30% (n=10) placebo @ 52wk
NCT04607837 · Phase 2 · registry result, not featured evidence
25.2% (n=127) vs 16.7% (n=60) placebo @ 52wk
NCT04607837 · Phase 2 · registry result, not featured evidence
Sustained Clinical Remission 17.9% (n=274) vs 2.2% (n=135) placebo2 mg
responder rate · % of participants
NCT03945188 · Phase 3 · monotherapy
show 2 more results
7.1% (n=28) vs 0% (n=14) placebo @ 40wk2 mg
NCT04706793 · Phase 3 · monotherapy
16.5% (n=127) vs 5% (n=60) placebo
NCT04607837 · Phase 2 · registry result, not featured evidence
Clinical Response 62.4% (n=274) vs 34.1% (n=135) placebo @ 12wk2 mg
responder rate · % of participants
NCT03945188 · Phase 3 · monotherapy
show 8 more results
48.2% (n=274) vs 23% (n=135) placebo @ 52wk2 mg
NCT03945188 · Phase 3 · monotherapy
62.2% (n=222) vs 41.1% (n=112) placebo @ 12wk2 mg
NCT03996369 · Phase 3 · monotherapy
52.6% (n=19) vs 7.1% (n=14) placebo @ 12wk2 mg
NCT05061446 · Phase 2 · registry result, not featured evidence
50.6% (n=50) vs 32.5% (n=54) placebo @ 12wk2 mg
NCT02447302 · Phase 2 · registry result, not featured evidence
33.3% (n=15) vs 7.1% (n=14) placebo @ 12wk1 mg
NCT05061446 · Phase 2 · registry result, not featured evidence
43.7% (n=52) vs 32.5% (n=54) placebo @ 12wk1 mg
NCT02447302 · Phase 2 · registry result, not featured evidence
55.9% (n=127) vs 36.7% (n=60) placebo @ 12wk
NCT04607837 · Phase 2 · registry result, not featured evidence
44.1% (n=127) vs 38.3% (n=60) placebo @ 52wk
NCT04607837 · Phase 2 · registry result, not featured evidence
Sustained Clinical 44.9% (n=274) vs 18.5% (n=135) placebo2 mg
responder rate · % of participants
NCT03945188 · Phase 3 · monotherapy
Sustained Mucosal Healing 13.5% (n=274) vs 2.2% (n=135) placebo2 mg
responder rate · % of participants
NCT03945188 · Phase 3 · monotherapy
Endoscopic Normalization 14.6% (n=274) vs 4.4% (n=135) placebo @ 12wk2 mg
responder rate · % of participants
NCT03945188 · Phase 3 · monotherapy
show 4 more results
26.3% (n=274) vs 5.9% (n=135) placebo @ 52wk2 mg
NCT03945188 · Phase 3 · monotherapy
17.1% (n=222) vs 8% (n=112) placebo @ 12wk2 mg
NCT03996369 · Phase 3 · monotherapy
0% (n=19) vs 0% (n=14) placebo @ 12wk2 mg
NCT05061446 · Phase 2 · registry result, not featured evidence
0% (n=15) vs 0% (n=14) placebo @ 12wk1 mg
NCT05061446 · Phase 2 · registry result, not featured evidence
Sustained Endoscopic Normalization 10.6% (n=274) vs 1.5% (n=135) placebo2 mg
responder rate · % of participants
NCT03945188 · Phase 3 · monotherapy
Complete Symptomatic Remission 5.8% (n=274) vs 2.2% (n=135) placebo @ 2wk2 mg
responder rate · % of participants
NCT03945188 · Phase 3 · monotherapy
show 16 more results
11.3% (n=274) vs 4.4% (n=135) placebo @ 4wk2 mg
NCT03945188 · Phase 3 · monotherapy
16.8% (n=274) vs 6.7% (n=135) placebo @ 8wk2 mg
NCT03945188 · Phase 3 · monotherapy
23% (n=274) vs 6.7% (n=135) placebo @ 12wk2 mg
NCT03945188 · Phase 3 · monotherapy
21.2% (n=274) vs 5.9% (n=135) placebo @ 16wk2 mg
NCT03945188 · Phase 3 · monotherapy
22.3% (n=274) vs 4.4% (n=135) placebo @ 20wk2 mg
NCT03945188 · Phase 3 · monotherapy
22.3% (n=274) vs 8.1% (n=135) placebo @ 24wk2 mg
NCT03945188 · Phase 3 · monotherapy
23% (n=274) vs 3% (n=135) placebo @ 32wk2 mg
NCT03945188 · Phase 3 · monotherapy
21.2% (n=274) vs 5.9% (n=135) placebo @ 40wk2 mg
NCT03945188 · Phase 3 · monotherapy
19.7% (n=274) vs 2.2% (n=135) placebo @ 48wk2 mg
NCT03945188 · Phase 3 · monotherapy
24.5% (n=274) vs 4.4% (n=135) placebo @ 52wk2 mg
NCT03945188 · Phase 3 · monotherapy
4.5% (n=222) vs 1.8% (n=112) placebo @ 2wk2 mg
NCT03996369 · Phase 3 · monotherapy
11.7% (n=222) vs 3.6% (n=112) placebo @ 4wk2 mg
NCT03996369 · Phase 3 · monotherapy
14% (n=222) vs 7.1% (n=112) placebo @ 8wk2 mg
NCT03996369 · Phase 3 · monotherapy
18% (n=222) vs 8.9% (n=112) placebo @ 12wk2 mg
NCT03996369 · Phase 3 · monotherapy
20.5% (n=127) vs 20% (n=60) placebo @ 52wk
NCT04607837 · Phase 2 · registry result, not featured evidence
20.5% (n=127) vs 20% (n=60) placebo @ 12wk
NCT04607837 · Phase 2 · registry result, not featured evidence

+ 10 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: amiselimod's landscape · etrasimod's landscape